Slaying RAS with a synthetic lethal weapon

Cell Research

Volumn 20, Issue 2, 2010, Pages 119-121

  Bommi Reddy, Archana ^a   Kaelin Jr , William G ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Howard Hughes Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN P21;

ANIMAL; ARTICLE; CELL SURVIVAL; CELL TRANSFORMATION; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFECT; GENETICS; HUMAN; MAMMAL; METHODOLOGY; NEOPLASM; SYNTHESIS;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; DRUG DELIVERY SYSTEMS; HUMANS; MAMMALS; NEOPLASMS; ONCOGENE PROTEIN P21(RAS);

EID: 76449110682     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2010.16     Document Type: Article

References (15)

1. Kaelin WG, Jr Synthetic lethality: a framework for the development of wiser cancer therapeutics. Genome Med 2009; 1:99.
2. Hartwell LH, Szankasi P, Roberts CJ, Murray AW, Friend SH. Integrating genetic approaches into the discovery of anticancer drugs. Science 1997; 278:1064-1068.
3. Kaelin WG, Jr The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005; 5:689-698.
4. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411:494-498.
5. Luo J, Emanuele MJ, Li D, et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009; 137:835-848.
6. Scholl C, Frohling S, Dunn IF, et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009; 137:821-834.
7. Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 2008; 9:517-531.
8. Barbie DA, Tamayo P, Boehm JS, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009; 462:108-112.
9. Meylan E, Dooley AL, Feldser DM, et al. Requirement for NF-B signalling in a mouse model of lung adenocarcinoma. Nature 2009; 462:104-107.
10. Baud V, Karin M. Is NF-B a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 2009; 8:33-40.
11. Mayo MW, Norris JL, Baldwin AS. Ras regulation of NF-kappa B and apoptosis. Methods Enzymol 2001; 333:73-87.
12. Chien Y, White MA. Characterization of RalB-Sec5-TBK1 function in human oncogenesis. Methods Enzymol 2008; 438:321-329.
13. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008; 359:1367-1380.
14. Hideshima T, Ikeda H, Chauhan D, et al. Bortezomib induces canonical nuclear factor-B activation in multiple myeloma cells. Blood 2009; 114:1046-1052.
15. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361:123-134.